keyword
MENU ▼
Read by QxMD icon Read
search

Opdivo

keyword
https://www.readbyqxmd.com/read/27899770/-universal-health-coverage-and-cancer-drugs-a-cost-effectiveness-perspective
#1
Ayako Fukuda, Ataru Igarashi
Japanese health system has been evaluated to be the closest to the ideal Universal Health Coverage(UHC)in the world. "Ideal UHC" is to ensure that all people could obtain the health services they need without suffering any financial hardship. However, maintaining current healthcare system, under which all medications are covered, is getting difficult due to the aging society and the existence of high-price drugs such as anti-cancer agents. Approval of OPDIVO(nivolumab)has raised the national discussion in Japan because of the possibility that the use of OPDIVO might collapse overall healthcare system...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/27824827/opdivo-s-lung-cancer-aspirations-dashed
#2
(no author information available yet)
No abstract text is available yet for this article.
November 8, 2016: Nature Biotechnology
https://www.readbyqxmd.com/read/27777773/antitumor-activity-of-nivolumab-on-hemodialysis-after-renal-allograft-rejection
#3
Michael Ong, Andrea Marie Ibrahim, Samuel Bourassa-Blanchette, Christina Canil, Todd Fairhead, Greg Knoll
BACKGROUND: Nivolumab (Opdivo™) is a novel IgG4 subclass programmed death-1 (PD-1) inhibiting antibody that has demonstrated breakthrough-designation anti-tumor activity. To date, clinical trials of nivolumab and other checkpoint inhibitors have generally excluded patients with solid organ transplantation and patients with concurrent immunosuppression. However, organ transplant recipients are at high-risk of development of malignancy as a result of suppressed immune surveillance of cancer...
2016: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/27739129/anti-pd1-induced-psoriasis-a-study-of-21-patients
#4
Julie Bonigen, Christine Raynaud-Donzel, José Hureaux, Nora Kramkimel, Astrid Blom, Géraldine Jeudy, Anne-Laure Breton, Thomas Hubiche, Christophe Bedane, Delphine Legoupil, Anne Pham-Ledard, Julie Charles, Maurice Pérol, Emilie Gérard, Patrick Combemale, Daphné Bonnet, Michèle-Léa Sigal, Emmanuel Mahé
Nivolumab (Opdivo(®) ), pembrolizumab (Keytruda(®) ), atezolizumab, and pidilizumabab are anti-PD1 monoclonal antibodies. Nivolumab is licensed in advanced melanoma and second-line therapy of advanced or metastatic non-small cell lung cancer. When activated, the programmed cell death (PD)-1 is implicated in the inhibition of the immune system. Anti-PD1 removes this inhibition and allows the immune system to control tumour cell progression.(1-4) Immune-mediated toxicity of this treatment have been reported, either organ-specific toxicities - i...
October 14, 2016: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/27692689/-psoriasis-and-psoriatic-arthritis-induced-by-nivolumab-opdivo-%C3%A2
#5
J-L Schmutz
No abstract text is available yet for this article.
December 2016: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/27680188/-immunooncology-in-urologic-cancers-current-status
#6
M-O Grimm
Immune checkpoint inhibitors are establishing itselves as a new systemic treatment option (in addition to chemotherapy and targeted therapy) for metastatic tumours. (Re)activating the immune system, these antibodies may lead to impressive remissions lasting for a long time in some patients. Regarding urological tumours, the anti-PD-1 antibody Nivolumab (Opdivo(®)) has been approved this year for advanced, previously treated renal cell carcinoma. In the United States, Atezolizumab (Tecentriq(®)) has been approved for metastatic urothelial carcinoma after platinum-based chemotherapy...
September 2016: Aktuelle Urologie
https://www.readbyqxmd.com/read/27370898/-cancer-immunotherapy-rational-and-recent-breakthroughs
#7
C Granier, S Karaki, H Roussel, C Badoual, T Tran, M Anson, E Fabre, S Oudard, E Tartour
Cancer immunotherapy has occupied a marginal therapeutic option in cancer despite strong arguments documenting the role of the immune system in controlling the proliferation of cancers. The recent success of immunotherapy results from a change in the past paradigm. From now on, the goal is not only to activate the immune system against tumor, but also to take account of the immunosuppressive tumor microenvironment Among these mechanisms, negative costimulatory molecules (CTLA-4, PD-1, etc.) expressed by T cells in the tumor could explain their lack of effectiveness in inhibiting tumor growth...
June 28, 2016: La Revue de Médecine Interne
https://www.readbyqxmd.com/read/27313464/profile-of-nivolumab-in-the-treatment-of-metastatic-squamous-non-small-cell-lung-cancer
#8
REVIEW
Yvonne Le Ang, Joline Sj Lim, Ross A Soo
Until recently, the prognosis and treatment of patients with advanced-stage squamous cell lung cancers have been limited. An improvement in the understanding of the role of the immune system in tumor immunosurveillance has led to the development of the programmed death-1 (PD-1) immune checkpoint inhibitor nivolumab (Opdivo). Nivolumab is the first PD-1 inhibitor approved for the treatment of advanced-stage squamous cell non-small-cell lung cancer following platinum-based chemotherapy. In the key Phase III trial CHECKMATE 017, a better overall survival and progression-free survival were seen in patients treated with second-line nivolumab compared with docetaxel...
2016: OncoTargets and Therapy
https://www.readbyqxmd.com/read/27223114/nivolumab-for-metastatic-melanoma
#9
A K Gupta, D Daigle
Melanoma is an aggressive skin cancer with a generally poor prognosis at Stage III-IV disease. Traditionally, metastatic melanoma was treated by surgical resection, when possible, and with systemic chemotherapy. New developments in molecular biology have led to the identification of immune checkpoints which are exploited by malignant cells, allowing them to go undetected by the immune system. Nivolumab (Opdivo®) is a human monoclonal antibody which prevents immune inhibition by interacting with PD-1 on tumor cells; thus, increasing tumor-specific T cell proliferation...
March 2016: Skin Therapy Letter
https://www.readbyqxmd.com/read/27189706/nivolumab-a-review-in-advanced-nonsquamous-non-small-cell-lung-cancer
#10
Gillian M Keating
The programmed death (PD)-1 immune checkpoint inhibitor nivolumab (Opdivo(®)) is approved in the USA for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have progression on or after platinum-based chemotherapy and in the EU for the treatment of adults with locally advanced or metastatic NSCLC after prior chemotherapy. In previously-treated patients with advanced nonsquamous NSCLC, overall survival was significantly prolonged and the overall response rate was significantly higher in patients who received intravenous nivolumab 3 mg/kg every 2 weeks versus intravenous docetaxel in the pivotal CheckMate 057 trial...
June 2016: Drugs
https://www.readbyqxmd.com/read/27135835/nivolumab-anti-programmed-death-1-pd-1-monoclonal-antibody-immunotherapy-role-in-advanced-cancers
#11
Arun Rajan, Chul Kim, Christopher R Heery, Udayan Guha, James L Gulley
The development of immune checkpoint inhibitors has altered the landscape of treatment of advanced cancers. These drugs are well tolerated and have shown clinical activity against a wide variety of solid tumors and hematological malignancies. The durability of response is particularly impressive when compared to other forms of systemic therapy. Nivolumab (Opdivo) is an IgG4 antibody that causes immune checkpoint blockade by diminishing inhibitory signaling through the programmed death receptor-1 pathway. It is approved for treatment of recurrent non-small cell lung cancer, melanoma, and renal cell carcinoma...
September 2016: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/26834161/how-cancers-escape-immune-destruction-and-mechanisms-of-action-for-the-new-significantly-active-immune-therapies-helping-nonimmunologists-decipher-recent-advances
#12
REVIEW
Jonathan L Messerschmidt, George C Prendergast, Gerald L Messerschmidt
UNLABELLED: With the Food and Drug Administration and other worldwide regulatory authorities' approval of ipilimumab (Yervoy), sipuleucel-T (Provenge), nivolumab (Opdivo), and pembrolizumab (Keytruda), oncologic therapy has now moved into noncancer cell targets within the immune system. For many nonimmunologists, understanding how these vastly different therapies work to improve survival, like no other therapies have in the past, is a challenge. The present report reviews the normal function of the immune system, how cancers escape the normal immune system, and how these new therapies improve immune system reactions against cancers...
February 2016: Oncologist
https://www.readbyqxmd.com/read/26633687/nivolumab-opdivo-plus-ipilimumab-yervoy-for-metastatic-melanoma
#13
(no author information available yet)
No abstract text is available yet for this article.
December 7, 2015: Medical Letter on Drugs and Therapeutics
https://www.readbyqxmd.com/read/26629287/opdivo-nivolumab-second-pd-1-inhibitor-receives-fda-approval-for-unresectable-or-metastatic-melanoma
#14
Lisa A Raedler
No abstract text is available yet for this article.
March 2015: American Health & Drug Benefits
https://www.readbyqxmd.com/read/26514815/nivolumab-a-review-in-advanced-squamous-non-small-cell-lung-cancer
#15
REVIEW
Gillian M Keating
Nivolumab (Opdivo(®); Nivolumab BMS™) was the first programmed death (PD)-1 immune checkpoint inhibitor to be approved for use in advanced, squamous non-small cell lung cancer (NSCLC) following prior chemotherapy. In the pivotal CheckMate 017 trial, intravenous nivolumab 3 mg/kg every 2 weeks was associated with significantly better overall survival and progression-free survival and a significantly higher overall response rate than intravenous docetaxel in the second-line treatment of advanced, squamous NSCLC...
November 2015: Drugs
https://www.readbyqxmd.com/read/26256749/-pharmacological-profile-and-clinical-efficacy-of-human-anti-human-pd-1-antibody-nivolumab-opdivo%C3%A2-as-a-new-immune-checkpoint-inhibitor
#16
REVIEW
Takao Yoshida, Kenichi Koda, Shintaro Nakao, Yukiya Ohyama
No abstract text is available yet for this article.
August 2015: Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica
https://www.readbyqxmd.com/read/26220912/nivolumab-a-review-in-advanced-melanoma
#17
REVIEW
Lesley J Scott
An improved understanding of cancer genetics and immune regulatory pathways, including those associated with evasion of immune surveillance by tumours, has culminated in the development of several targeted therapies. One such strategy that acts to negate evasion of immune surveillance by tumours is inhibition of the programmed cell death receptor-1 (PD-1) checkpoint pathway. Intravenous nivolumab (Opdivo(®)), a PD-1 checkpoint inhibitor, is approved or in pre-registration in various countries for use in adult patients with advanced melanoma, with the recommended monotherapy dosage being a 60-min infusion of 3 mg/kg once every 2 weeks...
August 2015: Drugs
https://www.readbyqxmd.com/read/26079767/addendum-nivolumab-opdivo-for-metastatic-melanoma-and-metastatic-nsclc
#18
(no author information available yet)
No abstract text is available yet for this article.
June 22, 2015: Medical Letter on Drugs and Therapeutics
https://www.readbyqxmd.com/read/26052584/lung-cancer-immunotherapeutics-on-the-horizon-as-opdivo-advances-through-phase-2
#19
(no author information available yet)
No abstract text is available yet for this article.
2014: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/26035747/nivolumab-opdivo-for-metastatic-melanoma-and-metastatic-nsclc
#20
REVIEW
(no author information available yet)
No abstract text is available yet for this article.
June 8, 2015: Medical Letter on Drugs and Therapeutics
keyword
keyword
83991
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"